Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Reports Positive Data For High-Concentration Adalimumab

Phase III Trials Cover Two Delivery Methods For CT-P17

Executive Summary

Celltrion’s phase III study comparing the pharmacokinetics, efficacy and safety profile of its CT-P17 high-concentration adalimumab biosimilar to Humira has yielded positive results. The company is presenting the results at the American College of Rheumatology Convergence 2020.

You may also be interested in...



Celltrion Wins Race For High-Concentration Adalimumab

Celltrion expects to receive the world’s first approval for a high-concentration adalimumab biosimilar rival to Humira, after receiving a positive opinion from the EMA’s CHMP for its CT-P17 candidate.

Alvotech Files Higher-Strength Adalimumab In US And EU

Alvotech has announced the filing of its AVT02 higher-strength adalimumab version of Humira 100mg/ml with both the FDA and the EMA, as well as disclosing expected decision dates. Teva will market the biosimilar in the US and Stada in Europe.

Alvotech Announces Two Successful Adalimumab Studies

Alvotech’s AVT02 proposed adalimumab biosimilar has seen positive results from two clinical trials. The high concentration dosage form of AVT02 differentes it from most of its biosimilar competitors.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel